Immix Biopharma Amends ATM Offering to Raise Capital

An update from Immix Biopharma ( (IMMX) ) is now available.

On March 25, 2026, Immix Biopharma amended its at-the-market offering agreement with Citizens JMP Securities, allowing the company to sell up to $100 million of its common stock from time to time through the firm as sales agent under an existing Form S-3 shelf registration. The stock may be sold in ordinary at-the-market transactions, as well as privately negotiated and block trades, subject to limits tied to registered share capacity, authorized but unissued shares, and Form S-3 eligibility thresholds.

Under the revised agreement, Citizens JMP Securities will use commercially reasonable efforts to execute sales in accordance with company instructions and applicable Nasdaq and securities law requirements, in return for a 3% commission on gross proceeds plus expense reimbursement up to $50,000. The structure provides Immix Biopharma with a flexible mechanism to raise additional equity capital over time, potentially supporting ongoing corporate and clinical initiatives while diluting existing shareholders as new shares are issued into the market.

The most recent analyst rating on (IMMX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.

More about Immix Biopharma

Immix Biopharma, Inc. is a Delaware-incorporated company operating in the biopharmaceutical sector, with its common stock listed on the Nasdaq Capital Market. The company finances its operations in part through equity capital markets transactions, including at-the-market offerings of its common stock under an effective shelf registration with the U.S. Securities and Exchange Commission.

Average Trading Volume: 885,019

Technical Sentiment Signal: Buy

Current Market Cap: $466.5M

See more insights into IMMX stock on TipRanks’ Stock Analysis page.